[1]
Gomez M.R.: Definition and criteria for diagnosis: natural history of
cerebral tuberous. W: Tuberous sclerosis complex. M.R. Gomez, J.R.
Sampson, V.H. Whittemore (red). University Press, New York 1999, 9.
[2]
Jóźwiak S.: Stwardnienie guzowate. W: Choroby nerwowo-skórne. R.
Michałowicz, S. Jóźwiak (red). CZD, Warszawa 1995.
[3]
Ahlsen G., Gillberg I.C., Lindbloom R. et al.: Tuberous sclerosis in
Western Sweden. A population study of cases with early childchood
onset. Arch. Neurol., 1994:51, 76.
[4]
Kwiatkowski D.J.: Tuberous sclerosis complex: from tubers to mTOR.
Ann. Hum. Genet., 2003:67, 87.
[5]
Dabora S.L., Jóźwiak S., Franz D.N. et al.: Mutational analysis in a
cohort of 224 tuberous sclerosis patients indicates increased severity
of TSC 2, compared with TSC1, disease in multiple organs. Am. J. Hum.
Genet., 2001:68, 64.
[6]
van Slegtenhorst M, de Hoogt R., Hermans C.et al.: Identification of
the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997,
277, 805-807
[7]
The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell, 1993:75, 1305.
[8]
Cheadle J.P., Reeve M.P., Sampson J.R. et al.: Molecular genetic advances in tuberous sclerosis. Hum. Genet., 2000:107, 97.
[9]
Domańska-Pakieła D.: Ocena obrazu klinicznego stwardnienia guzowatego w zależności od lokalizacji mutacji w obrębie genu TSC1 lub
TSC2. Praca doktorska, Instytut „Pomnik–Centrum Zdrowia Dziecka”,
Warszawa 2002.
[10]
Sancak O., Nellist M., Goedbloed M. et al.: Mutational analysis of TSC1
and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur. J. Hum. Genet., 2005:13, 731.
[11]
Jones A.C., Shyamsundar M.M., Thomas M.W. et al.: Comprehensive
mutatonal analysis of TSC1 and TSC2 and phenotypic correlations in
150 families with tuberous sclerosis. Am. J. Hum. Genet., 1999:64,
1305.
[12]
Rok P., Kasprzyk-Obara J., Domańska-Pakieła D. et al.: Clinical symptoms of tuberous sclerosis in patients with an identical TSC2 mutation.
Med. Sci. Monit., 2005:11, 230.
[13]
Knudson A.G.: Hereditary cancer: two hits revisited. J. Cancer Res.
Clinic. Oncol., 1996:122, 135.
[14]
Jóźwiak S., Schwartz R.A.: Dermatologic and stomatologic manifestation of tuberous sclerosis complex. W: Tuberous sclerosis complex:
from basic science to clinical phenotypes. P. Curatolo (red.). International Child Neurology. Mac Keith Press, London 2003.
[15]
Sepp T., Yates J.R., Green A.J.: Loss of heterozygosity in tuberous sclerosis hamartomas. J. Med. Genet., 1996:33, 962.
[16]
Jóźwiak S., Michałowicz R.: Skąpoobjawowe występowanie stwardnienia guzowatego w dwóch rodowodach. Neurol. Neurochir. Pol.,
1996:30, 917.
[17]
Webb D.W., Osborne J.P.: Non penetrance in tuberous sclerosis. J.
Med. Genet., 1991:28, 417.
[18]
Gomez M.R.: Varites of expression of tuberous sclerosis. Neurofibromatosis, 1998:1, 330.
[19]
Roach E.S., Gomez M.R., Northrup H.: Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J. Child. Neurol.,
1998:13, 624.
[20]
Castro A.F., Rebhun J.F., Clark G.J. et al.: Rheb binds tuberous sclerosis
complex 2(TSC2) and promotes S6 kinase activation in a rapamycin
and farnesylation dependent manner. J. Biol. Chem., 2003:278, 32493.
[21]
Zhang Y., Gao X., Saucedo L.J. et al.: Rheb is a direct target of the tuberous sclerosis tumor suppresor proteins. Nat. Cell Biol., 2003:5, 578.
[22]
Tee A.R., Manning B.D., Roux P.P. et al.: Tuberous sclerosis complex
gene products, tuberin and hamartin, control mTOR signaling by acting
as a GTPase-activating protein complex toward Rheb. Curr. Biol.,
2003:13, 1259.
[23]
van Slegtenhorst M., Nellist M., Nagelkerker B.: Interaction between
hamartin and tuberin , the TSC1 and TSC2 gene products. Hum. Mol.
Genet., 1998:7, 1053.
[24]
Jóźwiak J., Jóźwiak S., Grzela T. et al.: Positive and negative regulation
of TSC2 activity and its effectors of the mTOR pathway. Neuromolecular
Med., 2005:7, 287.
[25]
Jóźwiak J.: Hamartin and tuberin: working together for tumour suppression. Int. J. Cancer, 2006:118, 1.
[26]
Govindarajan B., Brat D., Csets M. et al.: Transgenic expression of dominant negative tuberin through a strong constitutive promoter results ia a
tissue – specific tuberous sclerosis phenotype in the skin and brain. J.
Biol. Chem., 2005:280, 5870.
[27]
El-Hashemite N., Walker V., Zhang H. et al.: Loss of TSC1 or TSC2 induces vascular endothelial growth factor production through mammalian
target of rapamycin. Cancer Res., 2003:63, 5173.
[28]
Curatolo P., Cusmai R., Cortesi F. et al.: Neuropsychiatric aspects of
tuberous sclerosis. Ann. NY Acard Sci., 1991:615, 8.
[29]
DiMario F.J.Jr.: Brain abnormalities in tuberous sclerosis complex. J.
Child. Neurol., 2004:19 (9), 650.
[30]
Luat A.F., Makki M., Chugani H.: Neuroimaging in uberous sclerosis
complex. Curr. Opin. Neurol., 2007:20, 142.
[31]
Barkovich A.J., Kuzniecky R.I., Jackson G.D. et al.: A developmental
and genetic classification for malformations of cortical development.
Neurology, 2005:65, 1873.
[32]
Park S.H., Pepkovitz S.H., Kerfoot C. et al.: Tuberous sclerosis in a 20-
week gestation fetus: immunohistochemical study. Acta Neuropathologica, 1997:94, 180.
[33]
Khanna P.C., Godinho S., Pungavkar S.A. et al.: Ultrafast MRI in the
prenatal diagnosis of Bourneville’s tuberous sclerosis. Neurol. India,
2005:53, 349.
[34]
Calcagnotto M.E., Paredes M.F., Tihan T. et al.: Dysfunction of synaptic
inhibition in epilepsy associated with focal cortical dysplasia. J. Neurosci., 2005:42, 9649.
[35]
White R., Hua Y., Schneithauer B. et al.: Selective alteration in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers. Ann. Neurol., 2001:49, 67.
[36]
Curatolo P., Bombardieri R., Verdecchia M. et al.: Intractable seizures in
tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment. J. Child. Neurol., 2005:20, 318.
[37]
Lee A., Maldonado M., Baybis M. et al.: Markers of cellular proliferation
are expressed in cortical tubers. Ann. Neurol., 2003:53, 668.
[38]
. Holmes G.L., Stafstrom C.E., and The Tuberous Sclerosis Study Group:
Tuberous sclerosis complex and epilepsy: recent developments and
future challenges. Epilepsia, 2007:48, 617.
[39]
Curatolo P., Verdecchia M., Bombardieri R.: Tuberous sclerosis complex: a revew of neurological aspects. Eur. J. Ped. Neurol., 2002:5, 15.
[40]
Cusmai R., Chiron C., Curatolo P. et al.: Topographic comparative study
of magnetic resonance imaging and electroencephalography in 34 children with tuberous sclerosis. Epilepsia, 1990:31, 747.
[41]
Bebin E.M., Kelly P.J., Gomez M.R.: Surgical treatment for epilepsy in
cerebral tuberous sclerosis. Epilepsia, 1993:34, 651.
[42]
Thiele E.A.: Managing epilepsy in tuberous sclerosis complex. J. Child.
Neurol., 2004:19, 680.
[43]
Weiner H.L., Carlson C., Ridgway E.B. et al.: Epilepsy surgery in young
children with tuberous sclerosis: results and novel approach. Pediatrics,
2006:117, 1494.
[44]
Levine D., Barnes P., Korf B. et al.: Tuberous sclerosis in the fetus:
second trimester diagnosis of subependymal nodules with ultrafast
MRI imaging. Am. J. Radiol., 2000:175, 1067.
[45]
O’Callaghan F.J.: Prevalence of subependymal giant cells astrocytomas
in TSC patients in the Wessex Region. J. Child Neurol., 2001:16, 678.
[46]
Goh S., Butler W., Thiele E.A.: Subependymal giant cell tumors in tuberous sclerosis complex. Neurology, 2004:63, 1457.
[47]
Webb D.W., Fryer A. E., Osborne J.: On incidence of fits and mental
retardation in tuberous sclerosis. J. Med. Genet., 1991:28, 395.
[48]
Cross J.H.: Neurocutaneous syndromes and epilepsy-issues in diagnosis and management. Epilepsia, 2005:46 (suppl. 10), 17.
[49]
Jóźwiak S, Schwartz R.A., Janniger C.K. et al.: Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J. Child
Neurol., 2000:15, 652.
[50]
Devlin L.A., Shepherd C.H., Crawford H. et al.: Tuberous sclerosis complex: clinical features, diagnosis, and prevalence in Northern Ireland.
Dev. Med. Child Neurol., 2006:48, 495.
[51]
Sparagana S.P., Delgado M.R., Batchelor L.L. et al.: Seizures remission
and antiepileptic drug discontinuation in children with tuberous sclerosis complex. Arch. Neurol., 2003:60, 1286.
[52]
Curatolo P., Seri S., Verdecchia M. et al.: Infantile spasms in tuberous
sclerosis complex. Brain Dev., 2001:23, 502.
[53]
Seri S., Cerquiglini A., Pisani F. et al.: Frontal lobe epilepsy associated
with tuberous sclerosis: electroecephalographic-magnetic resonance
fusioning. J. Child Neurol., 1998:13, 33.
[54]
Ohmori I., OhtsukaY., Ohno S. et al.: Analysis of ictal Eeg of epilepsy
associated with tuberous sclerosis complex. Epilepsia, 1998:39, 1277.
[55]
Jansen F.E., van Huffelen A.C., Bourez-Swart M. et al.: Consistent localization of interictal epileptiform activity on EEGs of patients with tuberous sclerosis. Epilepsia, 2005:46, 415.
[56]
Valencia I., Legido A., Yelin K. et al.: Anomalous inhibitory circuits in
cortical tubers of human tuberous sclerosis complex associated with
refractory epilepsy: aberrant expression of parvalbumin and calbidinD28k in dysplastic cortex. J. Child Neurol., 2006:49, 67.
[57]
Wang Y., Greenwood J.S., Calcagnotto M.E. et al.: Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice
lacking neuronal expression of TSC1. Ann. Neurol., 2007:61, 139.
[58]
Chiron C., Dulac O., Luna D. Et al.: Vigabatrin in infantile spasms. Lancet,
1990:335, 363.
[59]
Curatolo P., Verdecchia M., Bombardieri R.: Vigabatrin for tuberous sclerosis complex. Brain Dev., 2001:23, 649.
[60]
Hancock E., Osborne J.P.: Vigabatrin in the treatment of infantile spasms
in tuberous sclerosis: literature review. J. Child Neurol., 1999:14, 71.
[61]
Mackey M.T., Weiss S.K., Adams-Weber T. et al.: Practice parameter:
medical treatment of infantile spasms: report of the Americam Academy of
Neurology and the Child Neurology Society. Neurology, 2004:62, 1668.
[62]
Jambaque I., Chiron C., Dumas C. et al.: Mental and behavioural outcome of infantile epilepsy treated with vigabatrin in tuberous sclerosis
patients. Epilepsy Res. 2000:38, 151.
[63]
Lortie A, Plouin P., Chiron C. et al.: Characteristics of epilepsy in focal
cortical dysplasiain infancy. Epilepsy Res., 2002:51, 133.
[64]
Kossoff E.H., Thiele E.A., Pfeifer H.H. et al.: Tuberous sclerosis complex
and the ketogenic diet. Epilepsia, 2005:46, 1684.
[65]
Chugani D.C., Chugani H.T., Muzik O. et al.: Imaging epileptogenic tubers
in children with tuberous sclerosis complex using alpha-[11C]methyl-Ltryptophan positron emission tomography. Ann. Neurol., 1998:44, 858.
[66]
Jansen F.E., Braun K.P., van Nieuwenhuizen O. et al.: Diffusion-wieghted
magnetic resonance imaging and identification of the epileptogenic
tyber in patient with tuberous sclerosis. Arch. Neurol., 2003:60, 1580.
[67]
Jansen F.E., Huiskamp G., van Huffelen A.C. et al.: Identification of the
epileptogenic in patients with tuberous sclerosis: a comparisom of high
resolution EEG and MEG. Epilepsia, 2006:47, 108.
[68]
Wu J.Y., Sutherling W.W., Koh S. et al.: magnetic source imaging lokalizes epileptogenic zone in children with tuberous sclerosis complex.
Neurology, 2006:66, 1270.
[69]
Lazarowski A., Lubieniecki F., Camarero S. et al.: Multidrug resistance
proteins in tuberous sclerosis and refractory epilepsy. Pediatr. Neurol.,
2004:30, 102.
[70]
Raznahan A., Higgins N.P., Yates J.R. et al.: Biological markers of inelectual disability in tuberous sclerosis. Psychol. Med., 2007:1.
[71]
Joinson C., O’Callaghan F.J., Osborne J.P. et al.: Learning disability and
epilepsy in an epidemiological sample individuals with tuberous sclerosis complex. Psychol. Med., 2003:33, 335.
[72]
Humphrey A., Neville B.G., Clarke A. et al.: Autistic regression associated with seizure onset in an infant with tuberous sclerosis. Dev. Med.
Child Neurol., 2006:48, 609.
[73]
Deonna T., Roulet-Perez E., Chappuis H. et al.: Autistic regression associated with seizure onset in an infant with tuberous sclerosis. Dev. Med.
Child Neurol., 2007:49, 320.
[74]
Curatolo P., Porfirio M.C., Manzi B. et al.: Autism in tuberous sclerosis.
Eur. J. Ped. Neurol., 2004:8, 327.
[75]
Prather P., de Vries P.J.: Behavioural and cognitive aspects of tuberous
sclerosis complex. J. Child Neurol., 2004:19, 666.
[76]
Harrison J.E., O’Callaghan F.J., Hancock E. et al.: Cognitive deficits
in normally intelligent patients with tuberous sclerosis. Am. J. Med.
Genet., 1999:88, 642.
[77]
Bruni O., Cortesi F., Gianotti F. et al.: Sleep disorders in tuberous sclerosis: a polysomnographic study. Brain Dev., 1995:17, 52.
[78]
Domańska-Pakieła D., Kotulska K., Jóźwiak S. et al.: Zmiany skórne w
stwardnieniu guzowatym – przydatność kliniczna, współczesne poglądy
na patomechanizm powstawania i leczenia. Przeg. Derm., 2007:94,
689.
[79]
Jóźwiak S., Schwartz A., Janniger C.K. et al.: Skin lesions in children
with tuberous sclerosis complex: their prevalence, natural course, and
diagnostic significance. Int. J. Dermatol., 1998:37, 911.
[80]
Webb D.W., Clarke A., Fryer A. et al.: The cutaneous features of tuberous sclerosis: a population study. Br. J. Dermatol., 1996:135, 1.
[81]
Alper J.C., Holmes L.B.: The incidence and significance of birthmarks in
a cohort of 4 641 newborns. Pediatr. Dermatol., 1983:1, 58.
[82]
Norio R., Oksanen T., Rantanen J.: Hypopigmented skin alteration
resembling tuberous sclerosis in normal skin. J. Med. Genet., 1996:33,
184.
[83]
Vanderhooft S.L., Francis J.S., Pagon R.A. et al.: Prevalence of hypopigmented macules in a healthy population. J. Pediatr., 1996:129, 355.
[84]
Nikel W.R., Reed W.B.: Tuberous sclerosis. Arch. Dermatol., 1962:85,
209.
[85]
Kwiatkowski D.J., Shorty M.P.: Tuberous sclerosis. Arch. Dermatol.,
1994:130, 348.
[86]
Ward P.E., McCarthy D.J.: Periungual fibroma. Cutis, 1990:46, 118.
[87]
Schwartz A.R., Fernandez G., Kotulska K. et al.: Tuberous sclerosis complex: advances in diagnosis, genetics and management. J. Am. Acad.
Dermatol., 2007:57, 189.
[88]
Bordarier C., Lelouch-Tubiana A., Robain O.: Cardiac rhabdomyoma and
tuberous sclerosis in three fetuses: a neuropathological study. Brain
Dev., 1994:15, 467.
[89]
Czechowski J., Langille L., Varady E.: Intracardiac tumour and brain
lesions in tuberous sclerosis. Acta Radiol., 2000:41, 371.
[90]
Gushmann M., Entezami M., Becker L. et al.: Intrauterine rhabdomyoma
of the heart. A case report. Gen. Diagn. Pathol., 1997:143, 255.
[91]
PullicinoP., Curatolo P., Brinchi V. et al.: Antenatal diagnosis of tuberous
sclerosis. Lancet, 1992:341, 176.
[92]
Chao A.S., Chao A., Wang T.H. et al.: Outcome of antenatally diagnosed cardiac rhabdomyoma: case series and mata-analysis. Ultrasound
Obstet. Gynecol., 2008:31, 289.
[93]
Bader R.S., Chitayat D., Kelly E. et al.: Fetal rhabdomyoma: prenatal
diagnosis, clinical outcome, and incidence associated with tuberous
sclerosis complex. J. Pediatr. 2003:143, 620.
[94]
Muhler M.R., Rake A., Schwabe M. et al.: Value of fetal cerebral MRI
in sonographically proven cardiac rhabdomyoma. Pediatr. Radiol.,
2007:37, 467.
[95]
Jóźwiak S., Kawalec W., Dłużewska J. et al.: Cardiac tumours in tuberous sclerosis: their incidence and course. Eur. J. Ped., 1994:153, 155.
[96]
Bosi G., Lintermans J.P., Pellegrino P.A. et al.: The natural history of cardiac rhabdomyoma with and without tuberous sclerosis. Acta Pediatr.,
1996:85, 928.
[97]
DiMario F.J., Diana D., Leopold H. et al.: Evolution of cardiac rhabdomyoma in tuberous sclerosis complex. Clinical Pediatr., 1996:12, 615.
[98]
Jóźwiak S., Kotulska K., Kasprzyk-Obara J. et al.: Clinical and genotype
studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics, 2006:118, 1146.
[99]
. Hishitani T., Hoshinomi K., Okagawa K. et al.: Rapid emlargement of
cardiac rhabdomyoma during corticotropin therapy for infantile spasms.
Pediatr. Cardiol., 1997:13, 72.
[100]
Shepherd C.W., Gomez M.R., Lie J.T. et al.: Causes of death in patients
with tuberous sclerosis. Mayo Clin. Proc., 1991:66, 792.
[101]
Bissler J.J., Kingswood J.C.: Renal angiolipomata. Kidney Int., 2004:66,
924.
[102]
Rakowski S.K., Winterkorn E.B., Paul E. et al.: Renal manifestations of
tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int., 2006:70, 1777.
[103]
Cook J.A., Oliver K., Mueller R.F. et al.: A cross section study of renal
involvement in tuberous sclerosis. J. Med. Genet., 1996:33, 480.
[104]
Lemaitre L., Robert Y., Dubrulle F. et al.: Renal angiolipoma: growth followed up with CTand/or US. Radiology, 1995:197, 598.
[105]
Ewalt D.H., Diamond N., Ress C. et al.: Long term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis
complex. J. Urol., 2005:174, 1764.
[106]
Williams J.M., Racadio J.M., Johnson N.D. et al.: Embolization of renal
angiomyolipomata in patients with tuberous sclerosis complex. Am. J.
Kidney Dis., 2006:47, 95.
[107]
Winterkorn E.B., Daouk G.H., Anupindi S. et al.: Tuberous sclerosis complex and renal angiomyolipoma: case report and revew of the literature.
Pediatr. Nephrol., 2006:21, 1189.
[108]
Blethyn J., Jones A., Sulivan B.: Prenatal diagnosis of unilateral renal
disease in tuberous sclerosis. Br. J. Radiol., 1990:64, 161.
[109]
Sampson J.R., Maheshwar M.M., Aspinwall R. et al.: Renal cystic
disease in tuberous sclerosis: role of the polycystic kidney disease 1
gene. Am. J. Hum. Genet., 1997:61, 843.
[110]
Bisceglia M., Galliani C.A., Senger C. et al.: Renal cystic disease: a
review. Adv. Anat. Pathol., 2006:13, 26.
[111]
Crino P.B., Nathanson K.L., Henske E.P.: The tuberous sclerosis complex. N. Engl. J. Med., 2006:355, 1345.
[112]
Bjornsson J., Short M.P., Kwiatkowski D.J. et al.: Tuberous sclerosis
– associated renal cell carcinoma. Am. J. Pathol., 1996:149, 1201.
[113]
Kiribuschi K., Uchida Y., Fukuyma Y. et al.: High incidence of fundus
hamartomas and clinical significance of a fundus score in tuberous
sclerosis. Brain Dev., 1986:8, 509.
[114]
Rowley S.A. O’Callaghan F.J., Osborne J.P.: Ophtamic manifestations
of tuberous sclerosis: a population based study. Br. J. Ophtalmol.,
2001:85, 420.
[115]
Szreter M., Jóźwiak S., Micałowicz R.: Objawy okulistyczne u chorych
ze stwardnieniem guzowatym. Klin. Oczna, 1996:96, 315.
[116]
Miyake M., Tateishi U., Maeda T. et al.: Pulmonary lymphangioleiomyomatosis in a male patient with tuberous sclerosis complex. Radiat.
Med., 2005:23, 525.
[117]
Astrinidis A., Khare L., Carsilio T. et al.: Mutational analysis of the tuberous sclerosis gene TSC2 in patients withpumonary lymphangioleiomyomatosis. J. Med. Genet., 2000:37, 55.
[118]
Franz D.N., Brody A., Meyer C. et al.: Mutational and radiographic analysis of pulmonary diseae consistent with lymphangioleiomyomatosis
and micronodular pneumocyte hyperplasia in women with tuberous
sclerosis. Am. J. Res. Crit. Care Med., 2001:164, 661.
[119]
Costello L.C., Hartman T.E., Ryu J.H.: High frequency of pulmonary
lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin. Proc., 2000:75, 591.
[120]
Avila N.A., Dwyer A.J., Rabel A. et al.: Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology, 2007:242, 277.
[121]
Yoshida S., Hayashi T., Ishii N. et al.: Bilateral renal angiomyolipoma
coexistent with pulmonary lymphangioleiomyomatosis and tuberous
sclerosis. Int. Urol. Nephrol., 2006:38, 413.
[122]
Karbowniczek M., Astrinidis A., Balsara B.R. et al.: Reccurent lympangiomyomatosis after transplantation: genetic analyses reveal a matastatic mechanism. Am. J. Respir. Crit. Care Med., 2003:167, 976.
[123]
Sato T., Seyama K., Fujii H. et al.: Mutation analysis of the TSC1 and
TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J. Hum. Genet., 2002:47, 20.
[124]
Finley G.A., York B., Karas R. H. et al.: Estrogen-induced smooth muscle
cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor – beta and ERK-1/2. J.
Biol. Chem., 2004:279, 23114.
[125]
Yates J.R.W.: Tuberous sclerosis. Eur. J. Hum. Genet., 2006:14, 1065.
[126]
Rener-Primec Z., Stare J., Neubauer D.: The risk of lower mental outcome in infantile spasms increased after three weeks of hypsarhytmia
duration. Epilepsia, 2006:47, 2202.
[127]
Humprey A., Neville B.G.R., Clarke A. et al.: Autistic regression associated with seizure onset in an infant with tuberous sclerosis. Dev. Med.
Child Neurol., 2006:48, 609.
[128]
Jóźwiak S., Domańska-Pakieła D., Kotulska K. et al.: Treatment before
seizures: new indication for antiepileptic therapy in children with tuberous sclerosis complex. Epilepsia, 2007:48, 1632.
[129]
Jóźwiak S., Respondek-Liberska M., Domańska-Pakieła D. et al.: May
we prevent epilepsy in tuberous sclerosis complex? Eur. J. Ped. Neurol.,
2008:12 (suppl. 1), 13.
[130]
Yates J.R., van Backel I., Sepp T. et al.: Female getmline mosaicism in
tuberous sclerosis confirmed by molecular genetic analysis. Hum. Mol.
Genet., 1997:6, 2265.
[131]
Kaczorowska M., Borkowska J., Domańska-Pakiłe D. et al.: Clinical characteristics of tuberous sclerosis complex in patients with no TSC1 or
TSC2 mutations identified. Neurol. Dziec., 2006:15, 15.
[132]
Jóźwiak J., Jóźwiak S., Oldak M.: Molecular activity of sirolimus and
its possible application in tuberous sclerosis treatment. Med. Res. Rev.,
2006:15, 287.
[133]
Goncharova E.A., Goncharov D.A., Lim P.N. et al.: Modulation of cell
migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol., 2006:34, 473.
[134]
Lee L. Sudentas P., Dabora S.L.: Combination of a rapamycin analog
(CCI-779) and interferon gamma is more effective than single agents in
treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer, 2006:45, 933.
[135]
Robb V.A., Karbowniczek M., Klein-Szanto A.J. et al.: Activation of the
mTOR signaling pathway in renalcell carcinoma. J. Urol., 2007:177,
346.
[136]
Weimbs T.: Regulation of mTOR by polystin-1: is polycystic kidney
disease a case of futile repair? Cell Cycle, 2006:5, 1
[137]
Kaur S., Lal L., Sassano A. et al.: Regulatory effects of mammalian
torget of rapamycin- activated pathways in type I and Ii interferon signaling. J. Biol. Chem., 2007:282, 1757.
[138]
Messina M.P., Rauktys A., Lee L. et al.: Tuberous sclerosis preclinical
studies: timing of treatment, combination of a rapamycin analog (CCI779) and interferon gamma, and comparison rapamycin to CCI-779.
BMC Pharmacol., 2007:6, 7.
[139]
Lee L., Sudentas P., Donohue B. et al.: Efficacy of rapamycin anolog
(CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes
Chromosomes Cancer, 2005:42, 213.
[140]
Wienecke R., Fackler I., Linsenmaier U. et al.: Antitumoral activity of
rapamycin in renal angiomyolipoma associated with tuberous sclerosis
complex. Am. J. Kidney Dis., 1006:48, 27.
[141]
Herry I., Neukirch C., Debray M.P. et al.: Dramatic effect of sirolimus on
renal angiomyolipomas in a patient with tuberous sclerosis complex.
Eur. I. Inter. Med., 2007:18, 76.
[142]
Bissler J.J., McCormack F.X., Young L.R. et al.: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
N. Eng. J. Med., 2008:358, 140.
[143]
Franz D.N., Leonard J., Tudor C. et al.: rapamycin causes regression
of astrocytomas in tuberous sclerosis complex. Ann. Neurol., 2006:59,
490.
[144]
Paul E., Thiele E.: Efficacy of sirolimus in treating tuberous sclerosis and
lymphangioleiomyomatosis. N. Eng. J. Med., 2008, 358, 190.
Scholar Google
PubMed